Aquatic Capital Management LLC Buys 61,927 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Aquatic Capital Management LLC increased its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 52.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 180,927 shares of the company’s stock after acquiring an additional 61,927 shares during the quarter. Aquatic Capital Management LLC’s holdings in Takeda Pharmaceutical were worth $2,395,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Versant Capital Management Inc bought a new position in Takeda Pharmaceutical during the fourth quarter worth $26,000. Wilmington Savings Fund Society FSB acquired a new stake in Takeda Pharmaceutical during the third quarter worth $40,000. Farther Finance Advisors LLC boosted its stake in Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock worth $47,000 after buying an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. acquired a new stake in Takeda Pharmaceutical during the fourth quarter worth $52,000. Finally, Cromwell Holdings LLC acquired a new stake in Takeda Pharmaceutical during the fourth quarter worth $61,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Up 0.9 %

TAK opened at $15.17 on Tuesday. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.58 and a fifty-two week high of $15.37. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The firm’s fifty day moving average price is $14.75 and its two-hundred day moving average price is $13.94. The company has a market capitalization of $48.27 billion, a P/E ratio of 37.93, a P/E/G ratio of 0.24 and a beta of 0.39.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Analyst Ratings Changes

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.